Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new press release entry was added announcing Regeneron's Dow Jones Best-in-Class recognition for seven consecutive years. An older press release about a TriNetX collaboration was removed from the listing.
    Difference
    2%
    Check dated 2026-05-14T22:53:25.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added a new press release: Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial, May 5, 2026 7:00 AM EDT. Removed the EYLEA HD® (aflibercept) FDA approval release, April 2, 2026 12:00 PM EDT.
    Difference
    2%
    Check dated 2026-05-07T20:05:48.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Three new press releases were added to the listing (Q1 2026 financial results; U.S. government drug-cost agreement with a free gene therapy; FDA approval of Otarmeni), and three older entries were removed from the page.
    Difference
    6%
    Check dated 2026-04-30T15:54:00.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Updated the press releases listing on the page by adding newer announcements (including Dupixent® approval in the U.S., a Phase 3 results update for cemdisiran, and an investor conference presentation). Removed older listed items related to previous approvals/investor presentations and a past press release entry from the current view.
    Difference
    6%
    Check dated 2026-04-23T14:48:13.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added two new press releases: Regeneron and Telix Announce Strategic Radiopharma Collaboration and Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU). Removed two older press releases: Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders and Dupixent (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS).
    Difference
    6%
    Check dated 2026-04-16T10:40:21.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Added two new press releases on April 2, 2026: 'Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions' and 'EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)'. Removed two older entries: 'Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)' and 'Regeneron Announces Investor Conference Presentations.'
    Difference
    6%
    Check dated 2026-04-09T08:00:07.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.